TY  - DATA
AU  - Dabrowska,Agata
ED  - Library of Congress.
TI  - FDA Risk Evaluation and Mitigation Strategies (REMS): description and effect on generic drug development  
T2  - Report / Congressional Research Service
PY  - 2018///-
CY  - [Washington, D.C.]
PB  - Congressional Research Service
KW  - United States
KW  - Food and Drug Administration
KW  - Generic drugs
KW  - Pharmaceutical industry
KW  - Materials management
N1  - The CRS report home page provides access to all versions published since 2018 in accordance with P.L. 115-141; CRDP Program record; Report includes bibliographical references
UR  - https://purl.fdlp.gov/GPO/gpo114373
ER  -